Previous Article | Next Article 
Journal of Virology, January 2000, p. 784-795, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Cell-Line-Specific Defect in the Intracellular
Transport and Release of Assembled Retroviral Capsids
Scott D.
Parker1 and
Eric
Hunter2,*
Division of Infectious Diseases, Department
of Medicine,1 and Department of
Microbiology,2 University of Alabama at
Birmingham, Birmingham, Alabama 35294
Received 15 July 1999/Accepted 12 October 1999
 |
ABSTRACT |
Retrovirus assembly involves a complex series of events in which a
large number of proteins must be targeted to a point on the plasma
membrane where immature viruses bud from the cell. Gag polyproteins of
most retroviruses assemble an immature capsid on the cytoplasmic side
of the plasma membrane during the budding process (C-type assembly),
but a few assemble immature capsids deep in the cytoplasm and are then
transported to the plasma membrane (B- or D-type assembly), where they
are enveloped. With both assembly phenotypes, Gag polyproteins must be
transported to the site of viral budding in either a relatively
unassembled form (C type) or a completely assembled form (B and D
types). The molecular nature of this transport process and the host
cell factors that are involved have remained obscure. During the
development of a recombinant baculovirus/insect cell system for the
expression of both C-type and D-type Gag polyproteins, we discovered an
insect cell line (High Five) with two distinct defects that resulted in
the reduced release of virus-like particles. The first of these was a
pronounced defect in the transport of D-type but not C-type Gag
polyproteins to the plasma membrane. High Five cells expressing wild-type Mason-Pfizer monkey virus (M-PMV) Gag precursors accumulate assembled immature capsids in large cytoplasmic aggregates similar to a
transport-defective mutant (MA-A18V). In contrast, a larger fraction of
the Gag molecules encoded by the M-PMV C-type morphogenesis mutant
(MA-R55W) and those of human immunodeficiency virus were transported to
the plasma membrane for assembly and budding of virions. When
pulse-labeled Gag precursors from High Five cells were fractionated on
velocity gradients, they sedimented more rapidly, indicating that they
are sequestered in a higher-molecular-mass complex. Compared to Sf9
insect cells, the High Five cells also demonstrate a defect in the
release of C-type virus particles. These findings support the
hypothesis that host cell factors are important in the process of Gag
transport and in the release of enveloped viral particles.
 |
INTRODUCTION |
The assembly of an infectious
retrovirus requires the coordinated expression of a minimum of three
open reading frames found within all retroviral genomes:
gag, pol, and env (55).
Retrovirus capsid assembly is directed by the gag gene
product, and expression of the gag gene product alone is
sufficient for retroviral immature capsid assembly in the cytoplasm,
followed by the budding and release of enveloped virus-like particles
(VLPs) from the plasma membrane (10, 17, 22, 23, 28, 39, 44, 48,
59). Retroviral Gag polyproteins, the product of gag
gene expression, are synthesized in the cytoplasm and self-associate
with one another by undefined molecular mechanisms to form a spherical
immature capsid containing genomic RNA. The Gag polyproteins contain a series of basic amino acids near the amino terminus, and most are
modified by cotranslational amino-terminal myristoylation, promoting an
association with cell membranes (21). In most retroviruses, Gag polyproteins interact specifically with the plasma membrane to
initiate the viral budding process, culminating in the release of an
extracellular immature VLP (reviewed in reference
25). During or immediately following viral budding,
the Gag polyproteins are cleaved by a viral proteinase into the
structural proteins that constitute a mature infectious virion, and the
spherical immature capsid condenses to form an asymmetric mature viral
core (reviewed in reference 56). In all
retroviruses, these mature structural proteins include the matrix
protein associated with the viral membrane; the major capsid protein
forming the asymmetric viral core; and the nucleocapsid protein
associated with the viral genomic RNA within the core (26).
The differential timing and cellular location of Gag polyprotein
assembly relative to the viral budding event separates retroviral morphogenesis into two types. For C-type retroviruses such as human
immunodeficiency virus type 1 (HIV-1) and Moloney murine leukemia
virus, Gag polyproteins are transported as monomers or small oligomers
to the plasma membrane, where capsid assembly begins and is completed
coincident with the viral budding process (16). For B- and
D-type retroviruses such as mouse mammary tumor virus and Mason-Pfizer
monkey virus (M-PMV), respectively, immature capsids assemble to
completion in the cytoplasm away from the plasma membrane
(13). The assembled capsids must then migrate to the plasma
membrane for budding and release. Despite these differences, there is
evidence that the fundamental assembly mechanism of all retroviruses is
the same: a single point mutation in the matrix protein of M-PMV (R55W)
converts particle assembly from D-type to C-type morphogenesis
(42). Thus, the differences in the assembly process of
C-type and D-type retroviruses may only be a matter of Gag polyprotein
targeting to an assembly site at the cellular membrane versus a site
deeper in the cytoplasm of the cell. However, expression of Gag
polyproteins in vitro demonstrates that while both C- and D-type Gag
polyproteins can assemble in vitro (2, 3, 19, 51, 53), M-PMV
Gag is a far more efficient substrate for an in vitro assembly reaction
(45). Assembly away from cell membranes has been observed
when C-type Gag polyproteins are overexpressed in insect cells (9,
44), but the efficient assembly of a C-type retrovirus may
require an interaction with host cell membranes or membrane-associated factors.
Molecular genetic studies of C- and D-type retroviral gag
genes indicate that the amino-terminal matrix domain is important in
directing Gag polyproteins to the plasma membrane. The matrix domain
resides at the periphery of the assembled or partially assembled
immature capsid and is intimately associated with the cell membrane
during and after the viral budding event (15, 36). Removal
of the myristic acid or the polybasic region near the amino terminus
attenuates HIV-1 Gag-membrane binding affinities and also interferes
with the active transport of Gag polyproteins to the cell membrane
(29, 32, 52, 62). Furthermore, alterations in the HIV-1
matrix domain can redirect Gag polyproteins to alternative sites
(4, 12, 25). Similar studies of M-PMV, the prototype D-type
retrovirus, also demonstrate that amino-terminal myristoylation is
necessary to direct the Gag polyproteins, in the form of assembled capsids, to the plasma membrane (41). Deletions within the
M-PMV matrix domain result in an unstable Gag polyprotein that is
rapidly degraded, and the transport characteristics cannot be assessed (43). However, when point mutations such as A18V are
introduced into the polybasic region of the matrix domain of M-PMV, the
myristoylated and assembled capsids are not transported to the plasma
membrane but instead accumulate in the cytoplasm at their site of
assembly (40).
Since C-type assembly is rarely seen with the expression of wild-type
M-PMV Gag, it is assumed that unassembled or partially assembled M-PMV
Gag polyproteins are excluded from the cellular transport process that
directs assembled capsids to the plasma membrane. Only after the
completion of immature-capsid assembly is a matrix domain motif
displayed for interaction with cellular transport elements. It has also
been suggested that M-PMV Gag polyproteins contain a cytoplasmic
targeting or retention signal (CTRS) that restricts transport to the
plasma membrane until immature capsid assembly is complete (6,
42). However, the exclusion of unassembled M-PMV Gag polyproteins
from the transport process can be overcome by the introduction of the
R55W point mutation described above, which undergoes C-type viral
budding at the plasma membrane. Thus, the R55W point mutation either
must alter a membrane transport signal, such that it is active in the
unassembled Gag polyprotein, or it must attenuate the function of a
CTRS. Alternative explanations for the R55W phenotype include an
alteration in assembly characteristics such that membranes are required
for assembly or that cytoplasmic assembly is less efficient and free
Gag monomers or small multimers are then available for transport to the
plasma membrane. However, an in vitro analysis of M-PMV Gag R55W
assembly shows that the altered matrix domain does not affect capsid
formation in the absence of membranes and confirms that the C-type
assembly process is due to an alteration in transport characteristics
(46). Thus, for M-PMV, the assembly phenotype as a C-type
versus D-type retrovirus depends only upon the functional activity of a
CTRS and/or the ability of cellular transport machinery to recognize unassembled Gag polyproteins versus assembled immature capsids.
Although some of the C-type and D-type retroviral Gag polyprotein
domains that affect transport to the plasma membrane have been
characterized, the elements of the cellular transport machinery that
interact with Gag polyproteins are not well understood. The expression
of retroviral Gag polyproteins in a variety of eukaryotic cell lines,
including insect cells, results in the assembly and release of
extracellular VLPs with ultrastructural characteristics identical to
those of virions produced from infected cell lines (9, 17, 49, 54,
60). The host cell factors necessary for Gag transport and the
release of extracellular particles must then be well conserved. Host
cell lines completely defective in the active transport of retroviral
immature capsids or unassembled Gag polyproteins have not been
described. Here we report on an insect cell line with a pronounced
defect in the transport of D-type but not C-type Gag polyproteins to
the plasma membrane.
 |
MATERIALS AND METHODS |
Plasmid DNA constructs.
All recombinant DNA-cloning
techniques followed established methods described elsewhere
(47). Restriction and modification enzymes were purchased
from New England Biolabs (Beverly, Mass.). A portion of the M-PMV
genome (50), containing the M-PMV gag, pro, and pol open reading frames, was removed
from pSHRMX, a modification of the genomic clone, pSHRM15
(39), by using the HhaI site at nucleotide 486 and an XhoI site engineered into the genome at the end of
the pol reading frame where nucleotides 5816 and 5817 (CT)
were converted to TC. The HhaI site was blunt ended with Klenow fragment (New England BioLabs), and the genomic fragment was
ligated with the pSP73 (Promega, Madison, Wis.) vector by using the
EcoRI (blunt ended with Klenow fragment) and SalI
sites to create plasmid pSP73GX. An SspI (pSP73 nucleotide
2012)-SphI (nucleotide 26) fragment from the pSP73
polylinker and flanking region was then ligated to the pSP73GX
SphI and XhoI (blunt ended with Klenow fragment)
sites to create pSP73GXS. The M-PMV sequence was then removed from
pSP73GXS with EcoRI sites, blunt ended with Klenow fragment,
and ligated with the pBacPAK1 baculovirus transfer vector (Clontech,
Palo Alto, Calif.) by using the BamHI site, blunt ended with
Klenow fragment, to create pBKMGXS. The pBKMGXS vector was made with
the wild-type M-PMV matrix domain, as well as A18V, R55W, and both A18V
and R55W matrix point mutations. The viral proteinase was inactivated
by a previously described point mutation (D26N) in the active site in
all M-PMV gag-pro-pol expression vectors (49).
The HIV-1 gag-pro-pol open reading frames were removed from
a proviral clone (HXB2Dgpt) (14) by engineering an
XbaI site near the gag initiation codon and then removing the sequence between the XbaI site and the
NdeI site at nucleotide 5122. The NdeI site was
blunt ended with Klenow fragment, and the gag-pro-pol
sequence was ligated with vector pSP72 (Promega) by using the
XbaI and Klenow fragment blunt-ended XhoI sites
to create plasmid pSP72HXBgag. The gag-pro-pol sequence was
removed from pSP72HXBgag with BamHI and NdeI
(blunt ended with Klenow fragment) sites and ligated with the
BamHI and StuI sites in the baculovirus transfer
vector pBacPAK9 (Clontech) to create plasmid pBKHXBgag. The HIV-1
proteinase-active site was inactivated with a D25N point mutation as
with the M-PMV gag transfer vectors.
Insect cell culture.
A sample of the Spodoptera
frugiperda (Sf9) insect cell line was purchased from the American
Tissue Type Collection. Sf9 cells were grown at 27°C in standard
tissue culture flasks with supplemented Grace's medium (JRH
Biosciences, Lenexa, Kans.) with 10% fetal bovine serum (Gibco BRL,
Gaithersburg, Md.). High Five (Trichoplusia ni) insect cells
(Invitrogen, Carlsbad, Calif.) were grown at 27°C in EX-CELL 405 medium from JRH without serum.
Generation of recombinant baculovirus.
Baculovirus plasmid
transfer vectors and predigested baculovirus genomic DNA were purchased
from Clontech (BacPAK system). Transfer vectors containing M-PMV or
HIV-1 gag-pro-pol open reading frames were cotransfected
with the predigested baculovirus genomic DNA into Sf9 cells with
Lipofectin (Clontech) as specified by the manufacturer. Recombinant
baculoviruses were purified by following a previously described
protocol for end-point dilution assays and screened for M-PMV or HIV-1
Gag expression by Western blot analysis of cell lysates
(30).
Western blot analysis of cell lysates and cell supernatants.
Sf9 and High Five cells were infected with recombinant baculovirus at a
multiplicity of infection of 5. At 40 h after infection, the cells
were lysed in protein gel-loading buffer (47) and the cell
culture medium was centrifuged through a 35% (wt/vol) sucrose cushion
in a Beckman TLA 100.3 rotor at 100,000 rpm for 30 min to pellet VLPs.
The pellets were resuspended in protein gel-loading buffer. Then 2% of
each cell lysate and VLP pellet was analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to a Protran BA85 nitrocellulose membrane (Schleicher & Schuell,
Dassel, Germany). The blots were probed with M-PMV and HIV-1
Gag-specific antisera and horseradish peroxidase-labeled secondary
antibodies and then developed with SuperSignal chemiluminescent reagents (Pierce, Rockford, Ill.).
EM of infected insect cells.
At 48 h after infection at
a multiplicity of infection of 5 with recombinant baculovirus
expressing M-PMV or HIV-1 gag genes, Sf9 and High Five
insect cells were washed in phosphate-buffered saline (PBS) (pH 7.1)
and resuspended in 1% glutaraldehyde (Sigma-Aldrich Corp., St. Louis,
Mo.) in PBS with 10 mg of tannic acid (Sigma) per ml for 1 h on
ice. The fixed cells were then washed in PBS, resuspended in 2% osmium
tetroxide in PBS with 5 mg of tannic acid per ml, and processed for
electron microscopy (EM) as described previously (7).
Metabolic labeling of insect cells and analysis of cell
lysates.
At 36 h after infection of 60-mm plates of Sf9 or
High Five cells with recombinant baculovirus expressing M-PMV or HIV-1
gag genes, cells were washed and starved in methionine-free
Grace's insect cell culture medium (Gibco BRL) for 30 min and then
incubated for 30 min in 35S protein-labeling mix
(EXPRE35S35S; NEN Life Science Products,
Boston, Mass.) at 100 µCi/300 µl per plate. For pulse-labeling, the
cells were then lysed on ice in 500 µl of capsid extraction buffer
(1% [vol/vol] Triton X-100 [Sigma], 10 mM Tris [pH 7.6], 1 mM
EDTA, 500 mM NaCl) for 30 min. For chase experiments, the cells were
incubated for 14 h in complete growth medium following
pulse-labeling and then lysed as above. Following cell lysis, the
lysates were centrifuged in a refrigerated microcentrifuge for 3 min at
14,000 rpm and 4°C. The supernatant was loaded onto sucrose
velocity gradients containing 5 to 20% (wt/vol) sucrose with 10 mM
Tris (pH 7.6), 500 mM NaCl, and 1% (vol/vol) Triton X-100 in a Beckman
SW41 tube. The gradients were centrifuged in a Beckman SW41 rotor at
25,000 rpm for 30 min at 4°C, and 1-ml fractions were collected by
hand from the top of the gradients. Each gradient fraction and the cell
culture medium were immunoprecipitated with rabbit anti-M-PMV
Pr78Gag or human anti HIV-1 polyclonal antisera and
analyzed by SDS-PAGE as described previously (1). The M-PMV
or HIV-1 Gag proteins were quantitated on the dried gels with a Storm
860 PhosphorImager and the data were analyzed by ImageQuant software
(Molecular Dynamics Inc., Sunnyvale, Calif.).
Transient proviral gene expression in mammalian cells.
Human
293T cells (11) were grown at 37°C under 5%
CO2 in Dulbecco's modified Eagle's medium (Gibco)
supplemented with 10% fetal bovine serum (Gibco). The cells were
transfected by M-PMV proviral plasmid DNA (pSHRM15 [described above])
by previously described techniques (5). At 36 h after
transfection, the cells were incubated in methionine-free Dulbecco's
modified Eagle's medium (Sigma) for 30 min and then pulse-labeled for
30 min with 250 µCi of 35S protein-labeling mix in 200 µl of methionine-free medium. After pulse-labeling, the cells were
lysed in capsid extraction buffer on ice for 30 min and centrifuged in
a microcentrifuge as described above. For chase experiments, the
labeling medium was removed and complete medium was added for 4 h,
after which the cells were lysed as above. The supernatant of each cell
lysate was centrifuged through a sucrose velocity gradient as described
above for insect cell lysates. Sucrose velocity gradient fractions and
cell culture medium were immunoprecipitated and analyzed as described
above for insect cells.
 |
RESULTS |
SDS-PAGE and Western blot analysis of both M-PMV and HIV-1
gag expression in Sf9 and High Five insect cells.
To
compare the relative amounts of M-PMV and HIV-1 Gag in infected cell
lysates and cell supernatants, 2% of each Sf9 and High Five cell
lysate and 2% of each cell medium pellet were analyzed by SDS-PAGE
followed by Western blotting and detection of Gag polyproteins with
Gag-specific antisera. The results (Fig.
1) show nearly equal amounts of Gag in
the cell lysate and supernatant of Sf9 cells for both M-PMV and HIV-1.
In contrast, M-PMV Gag was absent from the cell supernatant of High
Five cells and HIV-1 Gag levels in the supernatant were markedly
reduced compared to those in Sf9 cells. While this analysis does not
provide a quantitative measure of Gag release from infected cells, the
results clearly demonstrate the inefficiency of both HIV-1 and M-PMV
Gag release from High Five cells. In the case of M-PMV, Gag release was
blocked below the level of detection in this experiment whereas the
effect on HIV-1 Gag release was less dramatic.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
SDS-PAGE and Western blot analysis of insect cell
lysates and cell culture media. Following the expression of M-PMV Gag
in Sf9 cells, Pr78Gag can be seen in both the cell lysate
(lane 1) and the cell culture medium (lane 2). HIV Pr55Gag
can also be seen in the cell lysate (lane 3) and culture medium (lane
4) of Sf9 cells. In contrast, following the expression of M-PMV Gag in
High Five cells, Pr78Gag is seen in the cell lysate (lane
5) but is absent in the cell culture medium (lane 6). HIV
Pr55Gag is seen in the High Five lysate (lane 7) and cell
culture medium (lane 8), but the amount of Pr55Gag in the
culture medium is markedly reduced compared with that in Sf9 cells.
|
|
EM analysis of baculovirus-infected insect cells expressing
retroviral gag gene products.
To further study the
assembly and transport characteristics of M-PMV and HIV Gag
polyproteins in insect cell lines, both Sf9 and High Five cells
infected with recombinant baculovirus-expressing retroviral
gag gene products were fixed and imaged by thin-section EM.
In Sf9 cells, M-PMV Gag polyproteins had assembly and transport characteristics very similar to previously described results obtained from proviral genomic expression in mammalian cell lines (Fig. 2) (40, 42). M-PMV Gag
polyproteins with a wild-type matrix domain (Fig. 2A and B) assembled
within the cytoplasm of Sf9 cells, and this was followed by transport
of intact capsids to the plasma membrane for budding and release of
enveloped VLPs. When the A18V point mutation was introduced into the
matrix domain (Fig. 2C), capsid assembly was unaffected but transport
to the plasma membrane was completely deficient and viral capsids
accumulated within the cytoplasm of the infected cell. This phenotype
is identical to that described previously in mammalian cells
(40). With the R55W matrix point mutation, there was
evidence of D-type assembly with relatively small collections of
particles retained in the cytoplasm (Fig. 2E), as well as both D-type
and C-type budding at the plasma membrane (Fig. 2D). In mammalian
cells, R55W Gag expression resulted primarily in C-type Gag assembly at
the plasma membrane, with rare collections of particles in the
cytoplasm (39). EM images of insect cells expressing Gag
polyproteins with both A18V and R55W matrix point mutations (Fig. 2F)
are identical to images of cells expressing A18V Gag, and neither C-
nor D-type viral budding was seen at the cell surface. The behavior of
this double mutant in mammalian cells was the same as that observed in
insect cells (data not shown). Thus, the A18V mutation effectively blocks the transport of intact M-PMV capsids as well as individual unassembled or partially assembled Gag polyproteins to the cell surface
and is cis dominant when coexpressed with the R55W matrix point mutation.

View larger version (164K):
[in this window]
[in a new window]
|
FIG. 2.
Thin-section EM of Sf9 cells expressing M-PMV
gag genes. (A and B) Wild-type M-PMV Gag expression shows
fully assembled immature capsids budding from the plasma membrane
(arrowheads) and extracellular pseudovirions (arrowhead labeled ECV).
(C) A18V Gag expression shows assembled immature capsids accumulating
in the cytoplasm (arrowhead) with no evidence of viral budding at the
plasma membrane. (D and E) R55W Gag expression (D) shows both C-type
assembly at the plasma membrane (arrowhead labeled C) and the budding
of fully assembled immature capsids (arrowheads labeled as D),
extracellular pseudovirions (arrowhead labeled ECV), and rare
collections of assembled particles retained in the cytoplasm (E). (F)
Gag with both A18V and R55W point mutations shows cytoplasmic immature
capsids (arrowhead) with no evidence of viral budding.
|
|
In High Five insect cells, wild-type M-PMV Gag polyproteins assembled
into immature capsids but there was a striking block
to intracellular
transport (Fig.
3A). Wild-type immature
capsids
accumulated in the cytoplasm in large inclusions but were not
transported to the plasma membrane. This phenotype is similar
to that
seen with the A18V point mutation in these cells (Fig.
3B), as well as
in mammalian and Sf9 insect cells. In contrast,
some of the M-PMV Gag
polyproteins with the R55W matrix mutation
were transported to the
plasma membrane of High Five cells to
initiate C-type viral budding
(Fig.
3C to E). R55W Gag also assembled
as D-type immature capsids in
the cytoplasm, and D-type particle
retention in the cytoplasm is
evident. While there is some evidence
of completed capsids budding at
the plasma membrane, this may
represent the completion of C-type
assembly in advance of membrane
extrusion, since no capsids were seen
in transit to the plasma
membrane. M-PMV Gag with both A18V and R55W
point mutations (Fig.
3F) assembled in the cytoplasm of High Five
cells, and neither
C- nor D-type budding was seen at the plasma
membrane, consistent
with the dominant nature of the A18V mutation
discussed above.
Thus, High Five cells have a defect in the cytoplasmic
transport
of M-PMV Gag in the form of assembled immature capsids, which
is less pronounced for unassembled Gag polyproteins.

View larger version (150K):
[in this window]
[in a new window]
|
FIG. 3.
Thin-section EM of High Five cells expressing M-PMV
gag genes. (A and B) Both wild-type M-PMV Gag (A) and A18V
M-PMV Gag (B) expression show assembled immature capsids accumulating
in the cytoplasm with no evidence of viral budding at the plasma
membrane. (C to E) R55W Gag expression shows D-type assembly and
retention in the cytoplasm (arrowhead labeled as D) as well as C-type
viral budding at the plasma membrane (arrowheads labeled C) and
extracellular VLPs (arrowheads labeled ECV). (F) Gag with both A18V and
R55W point mutations shows accumulation of immature capsids in the
cytoplasm with no viral budding at the plasma membrane.
|
|
HIV-1 Gag polyproteins assembled in C-type fashion at the plasma
membrane of mammalian cells, and similar transport and assembly
characteristics were seen in Sf9 insect cells (Fig.
4A and B),
including the release of
enveloped extracellular VLPs. In contrast
to wild-type M-PMV, there was
clear evidence of HIV-1 Gag polyproteins,
in the form of numerous
C-type budding structures, at the plasma
membrane of High Five cells
(Fig.
4C). The amount of C-type viral
budding activity at the plasma
membrane in High Five cells (Fig.
4D) appeared similar to that seen in
Sf9 cells; however, as shown
in Fig.
1 and addressed below, the release
of these assembling
structures was significantly reduced. Evidence of
C-type budding
of HIV-1 and M-PMV R55W Gag polyproteins at the plasma
membrane
of High Five cells suggests that a common transport mechanism
is involved in both cases.

View larger version (95K):
[in this window]
[in a new window]
|
FIG. 4.
Thin-section EM of HIV-1 gag gene expression
in both Sf9 (A and B) and High Five (C and D) cell lines. In both cell
lines, C-type budding events are seen at the plasma membrane
(arrowheads labeled C) and extracellular VLPs (arrowheads labeled ECV)
are seen in the spaces between adjacent cells.
|
|
Metabolic labeling of Sf9 and High Five insect cells expressing
retroviral gag gene products.
To quantitatively
compare the kinetics of retroviral assembly and the release of
extracellular pseudovirions in the two different insect cell lines,
metabolic labeling studies were performed. Immediately following a
30-min labeling period or a 14-h chase period, Sf9 and High Five cells
were lysed in nonionic detergent, under conditions known to keep
intracellular immature capsids intact (40). The cell lysates
were fractionated by velocity sucrose gradient sedimentation, and each
fraction was analyzed together with a resuspension of the gradient
pellet and the cell culture medium by immunoprecipitation and SDS-PAGE.
After pulse-labeling of Sf9 cells, the soluble, unassembled wild-type
M-PMV Gag polyproteins remained in the fractions at the very top of the
5 to 20% sucrose velocity gradients and there was no discrete peak
within the gradient suggesting the accumulation of assembly
intermediates (Fig. 5A and B, panels 1).
In contrast, after a 14-h chase period, approximately 35% of the
Pr78Gag was found in assembled immature capsids, which
sedimented to lower fractions (fractions 4, 5, and 6) within the
gradient (Fig. 5A and B, panels 2). In addition, approximately 20% of
the total Pr78Gag was released into the culture medium
(Fig. 5C).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 5.
SDS-PAGE analysis and quantitation of wild-type M-PMV
Gag in insect and mammalian cell lysates and cell culture medium. After
metabolic labeling, cell lysates were centrifuged through a sucrose
gradient, and fractions were collected from the top of the gradient
tubes, beginning with fraction 1 and ending with the resuspension of
the gradient pellet. (A) Each gradient fraction and the cell culture
medium (labeled supn.) from the chase were separated by SDS-PAGE, and
the autoradiograms from the insect cell expression are shown. (B) The
intensity of the Gag band in each velocity gradient fraction is graphed
as a percentage of the total of all bands from the same pulse or chase
experiment, including the culture medium for chase experiments. (C) The
intensity of the Gag band representing each cell chase culture medium
is graphed as a percentage of the total of all Gag bands (cell lysate
fractions and culture medium) from the same chase experiment.
|
|
To compare expression in mammalian cells to that in insect cells, human
293T cells were transfected with M-PMV proviral DNA,
pulse-labeled, or
pulse-labeled and then chased for 4 h. The cell
lysates were
fractionated on velocity sucrose gradients as above.
In pulse-labeled
293T cells, the M-PMV Gag remained in unassembled
form at the top of
the gradient, as was seen with Sf9 cells, whereas
after a 4-h chase,
approximately 30% of the labeled M-PMV Gag
was found as assembled
capsids (Fig.
5B, panel 2, fractions 3,
4, and 5). Approximately 35%
of the Pr78 remaining after the chase
was released as VLPs in the
culture medium of the cells (Fig.
5C). The sedimentation profile of
M-PMV capsids assembled in insect
cells was confirmed by fractionating
purified M-PMV capsids from
baculovirus-infected insect cells in
parallel gradients. These
capsids were also localized to fractions 4, 5, and 6 (data not
shown). Thus, the assembly, intracellular transport,
and release
of M-PMV Gag in Sf9 insect cells and in mammalian cells is
similar.
The results obtained with High Five cells expressing wild-type M-PMV
Gag were significantly different. Whereas M-PMV Gag from
pulse-labeled
Sf9 cell lysates remained at the top of the gradient,
M-PMV Gag
polyproteins from pulse-labeled High Five cell lysates
sedimented into
the gradient to fractions 3, 4, and 5 (Fig.
5A,
panel 3, and Fig.
5B,
panel 1). This could reflect an accelerated
assembly of partial capsids
that now sediment into the gradient
or, more probably, the association
of Gag polyproteins with cellular
elements to yield complexes with a
higher mass. After the chase
period, M-PMV Gag polyproteins from the
High Five cell lysates
sedimented as assembled capsids with maximal
values in fractions
5 and 6 (Fig.
5B, panel 2). However, the peak of
Pr78 trailed
appreciably into the denser portion of the gradient and
significantly
more material was found in the pellet, possibly as a
consequence
of an association with cellular elements. Very little
(<2%) M-PMV
Pr78 could be detected in the culture medium of M-PMV
Gag-expressing
High Five cells following the chase (Fig.
5C).
Expression of HIV-1 Gag in SF9 cells yielded results very similar to
that described for M-PMV Gag above. In pulse-labeled
cells, the bulk of
Pr55
Gag was unassembled and was found in the top two
fractions of the
gradient (Fig.
6A and B,
panels 1). After a 14-h chase, approximately
20% of
Pr55
Gag remained soluble while approximately 15 to 20%
sedimented to
fractions 7, 8, and 9 (Fig.
6B, panel 2). This presumably
represents
the assembled immature capsids that remain cell associated
even
after the 14-h chase. One-third of the HIV-1 Gag from SF9 cells
was released into the cell culture medium as VLPs following the
14-h
chase (Fig.
6C).

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 6.
SDS-PAGE analysis and quantitation of HIV-1 Gag in
insect cell lysates and in cell culture medium. After metabolic
labeling, cell lysates were centrifuged through a sucrose gradient, and
fractions were collected from the top of the gradient tubes, beginning
with fraction 1 and ending with the resuspension of the gradient
pellet. (A) Each gradient fraction and the cell culture medium (labeled
supn.) from the chase were separated by SDS-PAGE, and the
autoradiograms are shown. (B) The intensity of the Gag band in each Sf9
and High Five (H5) velocity gradient fraction is graphed as a
percentage of the total of all bands from the same pulse or chase
experiment, including the culture medium for chase experiments. (C) The
intensity of the Gag band representing each cell chase culture medium
is graphed as a percentage of the total of all Gag bands (cell lysate
fractions and culture medium) from the same chase experiment.
|
|
In contrast to M-PMV, the bulk of the HIV-1 Gag polyprotein from
pulse-labeled High Five cell lysates remained in the first
two gradient
fractions (Fig.
6A, panel 3, and Fig.
6B, panel 1).
However,
approximately 20% did sediment into fractions 3, 4, 5,
and 6, raising
the possibility that a fraction of HIV-1 Gag also
associates with a
cellular component in High Five cells. Following
the 14-h chase period,
approximately 30% of Pr55 was found in
fractions 8 and 9 (Fig.
6B,
panel 2), again presumably representing
assembled but cell-associated
HIV Gag polyproteins. In contrast
to Sf9 cells, however, approximately
30% of the HIV-1 Gag was
found in the pellet fraction and there was
<2% soluble Pr55 at
the top of the gradient. This finding may be a
consequence of
Pr55 association with cellular elements in High Five
cells, as
discussed with M-PMV Gag above. Although extracellular VLPs
were
seen by EM, less than 6% of Pr55 was released into the High Five
culture medium (Fig.
6C). The reduced levels of both HIV and M-PMV
R55W
(see below) extracellular VLPs from High Five cells, despite
the EM
data presented above, suggest that these cells are also
somewhat
defective in the release of C-type
VLPs.
As discussed above, the A18V matrix mutation blocks the transport of
immature M-PMV capsids in all cell lines studied to date.
Velocity
gradient fractions from Sf9 cell lysates with A18V M-PMV
Gag had a
profile similar to that seen with the expression of
wild-type M-PMV
Gag, with the exception of an increase in the
number of immature
intracellular capsids in the Sf9 chase cell
lysate (Fig.
7A, panel 2, fractions 4, 5, and 6). In
contrast
to wild-type M-PMV Gag, less than 1% of the A18V
Pr78
Gag was released into the culture medium (Fig.
7B),
demonstrating
the effect of the intracellular transport block seen in
the EM
analysis (see above). The velocity gradient profiles of R55W Gag
in the pulse and chase Sf9 cell lysate fractions were not
significantly
different from those of wild-type M-PMV Gag, but there
was an
increase in the fraction of R55W Pr78
Gag released
into the culture medium after a 14-h chase (30% R55W
Pr78 released
[Fig.
7B]). The fraction of C-type R55W Pr78
Gag released
from Sf9 cells was similar to that seen with C-type
HIV-1
Pr55
Gag (see above).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 7.
SDS-PAGE analysis and quantitation of M-PMV Gag with
matrix mutations (A18V, R55W, and the A18V/R55W double mutant) in Sf9
and High Five (H5) cell lysates and in cell culture medium. After
metabolic labeling, cell lysates were centrifuged through a sucrose
gradient, and fractions were collected from the top of the gradient
tubes, beginning with fraction 1 and ending with the resuspension of
the gradient pellet. (A) Each gradient fraction and the cell culture
medium from the chase were separated by SDS-PAGE, and the relative
intensity of the Gag band in each velocity gradient fraction is graphed
as a percentage of the total of all bands from the same pulse or chase
experiment, including the culture medium for chase experiments. (B) The
intensity of the Gag band representing each cell chase supernatant is
graphed as a percentage of the total of all Gag bands (cell lysate
fractions and culture medium) from the same chase experiment.
|
|
The expression of the A18V and R55W matrix mutant M-PMV Gag
polyproteins in High Five cells yielded results similar to those
seen
with wild-type M-PMV Gag in these cells. In pulse-labeled
High Five
cells, both R55W and A18V Gag sedimented into fractions
3, 4, and 5 (Fig.
7A, panel 3). Although M-PMV R55W Gag and HIV-1
Gag both
demonstrated C-type assembly at the plasma membrane in
High Five cells,
the pulse-labeled velocity gradient profiles
were very different (Fig.
6B, panel 1 and Fig.
7A, panel 3). If
an interaction with a cellular
element(s) is responsible for the
M-PMV pulse-labeled velocity gradient
profile in High Five cells,
this interaction must not completely
interfere with the transport
of M-PMV R55W Gag to the plasma membrane.
While C-type budding
structures were seen with M-PMV R55W Gag in High
Five cells (see
the EM analysis above), less than 1% of the R55W Pr78
was released
into the High Five cell culture medium (Fig.
7B). As
discussed
above, High Five cells may have a defect in the release of
extracellular
VLPs that is independent from the M-PMV Gag transport
defect.
M-PMV Gag expression with a double matrix mutant (A18V and R55W)
yielded results very similar to those seen with the A18V
matrix mutant
alone (Fig.
7). Thus, the A18V mutation acts as
a dominant negative
transport block, which confirms the findings
in the EM analysis
above.
 |
DISCUSSION |
For most retroviruses (spumaviruses being the notable exception),
the release of an enveloped extracellular virus particle requires that
Gag polyproteins interact specifically with the plasma membrane during
the viral budding process. The fact that viral budding is limited only
to the plasma membrane argues that cellular transport mechanisms must
actively direct retroviral Gag polyproteins exclusively to this
cellular location. There are other lines of evidence to suggest that
host cell factors are involved in Gag polyprotein transport. Cell ATP
depletion studies demonstrate that ATP is required for M-PMV Gag
transport, suggesting an active involvement of cellular proteins with
ATPase activity in the process (57). HIV-1 Gag interacts
with both microtubules and microfilaments as a possible mechanism of an active-transport process (24, 27, 38, 58). In addition, a
Gag receptor residing exclusively at the plasma membrane may be
required to insert and anchor the Gag matrix domain into the plasma
membrane (proposed in reference 59). The directional budding and secretion of HIV-1 virions observed when infected monocytes
adhere to epithelial cell monolayers also suggests that the interaction
of host cell factors with retroviral Gag polyproteins is necessary to
coordinate the assembly and release of an enveloped extracellular VLP
(35). Although T-cell and monocyte cell lines in which HIV-1
Gag polyproteins are transported to alternative cell membranes for
viral budding have been reported (18, 31, 34), host cell
lines completely defective in the active transport of retroviral
immature capsids or unassembled Gag polyproteins have not been described.
In Sf9 insect cells, expression of either M-PMV or HIV gag
gene products results in D- or C-type immature-capsid assembly, respectively, followed by viral budding and release of extracellular VLPs (17, 49). Thus, these insect cells have the capacity for the transport of both C- and D-type Gag polyproteins to the plasma
membrane and allow the completion of the viral budding process, even in
the presence of baculovirus cytopathic effect. Compared with Sf9 cells,
High Five insect cells have a defect in the transport of assembled
capsids to the plasma membrane that interferes with the release of
extracellular VLPs. Imaging of High Five insect cells by thin-section
EM reveals that wild-type M-PMV immature capsids are assembled in the
cytoplasm but are not transported to the plasma membrane. In contrast,
similar numbers of budding structures were observed in EM studies of
both Sf9 and High Five cell lines expressing HIV-1 Gag and in cells
expressing M-PMV R55W Gag. Although not quantitative, these
observations suggest that Gag precursors that assemble at the plasma
membrane can be transported there with similar efficiency in both cell types. The R55W mutation allows at least a fraction of unassembled M-PMV Gag polyproteins to escape the transport defect in High Five
cells but not the transport defect imposed by the A18V mutation, suggesting that a different mechanism is involved for each defect. If
the effect of the A18V mutation is a lack of active transport to the
plasma membrane, the High Five cell defect may be a consequence of a
restrictive cytoplasmic retention mechanism that can be relieved by the
R55W mutation. As an alternative, there may be separate and independent
mechanisms for the transport of assembled capsids and unassembled Gag
polyproteins. High Five cells may then have a selective defect in the
macromolecular transport of assembled M-PMV capsids while the transport
of unassembled Gag polyproteins remains intact. In either case, it is
clear that High Five cells have a missing or altered host cell
factor(s) that participates in the transport of D-type particles but is
less important in the transport of unassembled Gag polyproteins.
The metabolic labeling experiments of insect cells expressing
gag gene products demonstrate another defect in the release of extracellular VLPs from High Five cells. A quantitative analysis of
the amount of M-PMV and HIV Gag in the culture medium of Sf9 cells
shows that a significant fraction of both C- and D-type Gag
polyproteins complete the viral budding process and are released as
extracellular pseudovirions. The same analysis in High Five cells shows
a marked reduction in the release of both C- and D-type VLPs. While the
absence of D-type M-PMV Gag in the culture medium of High Five cells is
explained by the transport defect observed by thin-section EM, the
marked reduction in C-type polyproteins is not. The metabolic labeling
experiments offer a more quantitative measurement of extracellular
particle release, and they suggest, when coupled with the EM data, that
although C-type Gag polyproteins are transported to the plasma membrane
of High Five cells and initiate viral budding, there is a defect in the
completion of viral budding and the release of enveloped VLPs. This
second cell-dependent defect is consistent with a number of previous
studies that have suggested a role for host cell factors in the
completion of the viral budding event (8, 20, 33, 37, 61).
Pulse-chase-labeled insect cell lysates were fractionated by sucrose
velocity gradient sedimentation to measure the proportion of Gag
polyproteins that have assembled into immature capsids during the chase
period. As a consistent but unexpected finding, M-PMV and to a lesser
extent HIV Gag polyproteins in pulse-labeled High Five cell lysates
sediment into the gradient by several fractions. In contrast, both
M-PMV and HIV-1 Gag in pulse-labeled Sf9 cell lysates remain in the top
fractions of the gradient, as expected after a short labeling period
with insufficient time allowed for capsid assembly. M-PMV capsid
assembly within a short labeling period is inconsistent with a previous
characterization of M-PMV assembly kinetics in mammalian cells
(40) and is an unlikely explanation of the M-PMV Gag
sedimentation characteristics in the pulse-labeled High Five cell
lysate velocity gradients. High Five cells have a moderate increase
(two- to threefold [data not shown]) in Gag expression levels
compared with Sf9 cells, but this difference is not likely to result in
accelerated immature capsid assembly. A more plausible explanation is
that M-PMV Gag and, to a lesser extent, HIV-1 Gag may bind to cellular
structures to form a complex with a higher S value shortly after
synthesis in High Five cells and that this association may persist
during cell lysis and velocity gradient sedimentation. Pulse-labeled M-PMV Gag binding to cellular structures may be a consequence of a
restrictive cytoplasmic retention system and may explain the D-type
transport defect observed in High Five cells. Although C-type M-PMV Gag
(R55W) is capable of being transported to the plasma membrane in High
Five cells, a significant number of particles are also retained in the
cytoplasm, which may explain the similar appearance of wild-type and
R55W M-PMV Gag in the High Five cell lysate velocity gradient analysis.
In conclusion, the High Five insect cell line has separate defects
involving the transport of retroviral Gag polyproteins to the plasma
membrane and the completion of the viral budding event. The transport
defect is most pronounced for D-type M-PMV Gag polyproteins, suggesting
that the efficiency of D-type Gag transport is sensitive to alterations
in host cell factors that are less important in C-type Gag transport.
The budding and release defect observed with C-type Gag polyproteins
argues that host cell factors can assist or interfere with the
efficient completion of the viral budding event and release of an
extracellular VLP. Host cell lines with specific and dramatic defects
in these late stages in the retroviral life cycle have not been
described to date, and the findings reported here provide convincing
evidence for the involvement of cellular factors during Gag transport
and viral budding. The High Five cell line may prove to be a useful tool in the search for specific host cell factors that assist or
interfere with the efficient intracellular transport of Gag polyproteins and with the production of an extracellular virus particle.
 |
ACKNOWLEDGMENTS |
We thank Eugene Arms and the UAB Comprehensive Cancer Center
electron microscopy facility for assistance with the electron microscopic analysis.
This work was supported by U.S. Public Health Service grants AI01263 to
S.D.P. and CA27834 to E.H.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, University of Alabama at Birmingham, 908 20th St. So., Birmingham, AL 35294. Phone: (205) 934-4321. Fax: (205) 934-1640. E-mail: Ehunter{at}UAB.edu.
 |
REFERENCES |
| 1.
|
Bradac, J., and E. Hunter.
1984.
Polypeptides of the Mason-Pfizer monkey virus I. Synthesis and processing of the gag-gene products.
Virology
138:260-275[CrossRef][Medline].
|
| 2.
|
Campbell, S., and A. Rein.
1999.
In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain.
J. Virol.
73:2270-2279[Abstract/Free Full Text].
|
| 3.
|
Campbell, S., and V. M. Vogt.
1997.
In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles.
J. Virol.
71:4425-4435[Abstract].
|
| 4.
|
Chazal, N.,
B. Gay,
C. Carriere,
J. Tournier, and P. Boulanger.
1995.
Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway.
J. Virol.
69:365-375[Abstract].
|
| 5.
|
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752[Abstract/Free Full Text].
|
| 6.
|
Choi, G.,
S. Park,
B. Choi,
S. Hong,
J. Lee,
E. Hunter, and S. S. Rhee.
1999.
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein.
J. Virol.
73:5431-5437[Abstract/Free Full Text].
|
| 7.
|
Compans, R. W.,
K. V. Holmes,
S. Dales, and P. W. Choppin.
1964.
An electron microscopic study of moderate and virulent virus-cell interactions of the parainfluenza virus SV5.
Virology
30:411-426.
|
| 8.
|
Craven, R. C.,
R. N. Harty,
J. Paragas,
P. Palese, and J. W. Wills.
1999.
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras.
J. Virol.
73:3359-3365[Abstract/Free Full Text].
|
| 9.
|
Delchambre, M.,
D. Gheysen,
D. Thines,
C. Thiriart,
E. Jacobs,
E. Verdin,
M. Horth,
A. Burny, and F. Bex.
1989.
The Gag precursor of simian immunodeficiency virus assembles into virus-like particles.
EMBO J.
8:2653-2660[Medline].
|
| 10.
|
Dickson, C.,
R. Eisenman,
H. Fan,
E. Hunter, and N. Teich.
1982.
Protein biosynthesis and assembly, p. 513-648.
In
R. Weiss, N. Teich, H. Varmus, and J. Coffin (ed.), RNA tumor viruses, 2nd ed, vol. 1. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 11.
|
DuBridge, R. B.,
P. Tang,
H. C. Hsia,
P. M. Leong,
J. H. Miller, and M. P. Calos.
1987.
Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.
Mol. Cell. Biol.
7:379-387[Abstract/Free Full Text].
|
| 12.
|
Facke, M.,
A. Janetzko,
R. Shoeman, and H. Krausslich.
1993.
A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum.
J. Virol.
67:4972-4980[Abstract/Free Full Text].
|
| 13.
|
Fine, D., and G. Schochetman.
1978.
Type D primate retroviruses: a review.
Cancer Res.
38:3123-3139[Abstract/Free Full Text].
|
| 14.
|
Fisher, A. G.,
L. Ratner,
H. Mitsuya,
L. M. Marselle,
M. E. Harper,
S. Broder,
R. C. Gallo, and F. Wong-Staal.
1986.
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects.
Science
233:655-659[Abstract/Free Full Text].
|
| 15.
|
Gelderblom, H.,
E. Hausmann,
M. Ozel,
G. Pauli, and M. Koch.
1987.
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.
Virology
156:171-176[CrossRef][Medline].
|
| 16.
|
Gelderblom, H. R.
1991.
Assembly and morphology of HIV: potential effect of structure on viral function.
AIDS
5:617-637[Medline].
|
| 17.
|
Gheyson, D.,
E. Jacobs,
F. d. Foresta,
C. Thiriart,
M. Francotte,
D. Thines, and M. D. Wilde.
1989.
Assembly and release of HIV-1 precursor Pr55gag virus like particles from recombinant baculovirus infected insect cells.
Cell
59:103-112[CrossRef][Medline].
|
| 18.
|
Grief, C.,
G. H. Farrar,
K. A. Kent, and E. G. Berger.
1991.
The assembly of HIV within the Golgi apparatus and Golgi-derived vesicles of JM cell syncytia.
AIDS
5:1433-1439[Medline].
|
| 19.
|
Gross, I.,
H. Hohenberg,
C. Huckhagel, and H.-G. Krausslich.
1998.
N-terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles.
J. Virol.
72:4798-4810[Abstract/Free Full Text].
|
| 20.
|
Harty, R. N.,
J. Paragas,
M. Sudol, and P. Palese.
1999.
A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding.
J. Virol.
73:2921-2929[Abstract/Free Full Text].
|
| 21.
|
Henderson, L.,
H. Krutzsch, and S. Oroszlan.
1983.
Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational protein modification.
Proc. Natl. Acad. Sci. USA
80:339-343[Abstract/Free Full Text].
|
| 22.
|
Hoshikawa, N.,
A. Kojima,
A. Yasuda,
E. Takayashiki,
S. Masuko,
J. Chiba,
T. Sata, and T. Kurata.
1991.
Role of the gag and pol genes of human immunodeficiency virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus: an ultrastructural study.
J. Gen. Virol.
72:2509-2517[Abstract/Free Full Text].
|
| 23.
|
Karacostas, V.,
K. Nagashima,
M. A. Gonda, and B. Moss.
1989.
Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.
Proc. Natl. Acad. Sci. USA
86:8964-8967[Abstract/Free Full Text].
|
| 24.
|
Kim, W.,
Y. Tang,
Y. Okada,
T. A. Torrey,
S. K. Chattopadhyay,
M. Pfleiderer,
F. G. Falkner,
F. Dorner,
W. Choi,
N. Hirokawa, and H. C. Morse, III.
1998.
Binding of murine leukemia virus Gag polyproteins to KIF4, a microtubule-based motor protein.
J. Virol.
72:6898-6901[Abstract/Free Full Text].
|
| 25.
|
Krausslich, H. G., and R. Welker.
1996.
Intracellular transport of retroviral capsid components.
Curr. Top. Microbiol. Immunol.
214:25-63[Medline].
|
| 26.
|
Leis, J.,
D. Baltimore,
J. Bishop,
J. Coffin,
E. Fleissner,
S. Goff,
S. Oroszlan,
H. Robinson,
A. Skalka,
H. Temin, and V. Vogt.
1988.
Standardized and simplified nomenclature for proteins common to all retroviruses.
J. Virol.
62:1808-1809[Abstract/Free Full Text].
|
| 27.
|
Liu, B.,
R. Dai,
C. J. Tian,
L. Dawson,
R. Gorelick, and X. F. Yu.
1999.
Interaction of the human immunodeficiency virus type nucleocapsid with actin.
J. Virol.
73:2901-2908[Abstract/Free Full Text].
|
| 28.
|
Mergener, K.,
M. Facke,
R. Welker,
V. Brinkmann,
H. R. Gelderblom, and H. G. Krausslich.
1992.
Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells.
Virology
186:25-39[CrossRef][Medline].
|
| 29.
|
Ono, A., and E. O. Freed.
1999.
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.
J. Virol.
73:4136-4144[Abstract/Free Full Text].
|
| 30.
|
O'Reilly, D. R.,
L. K. Miller, and V. A. Luckow.
1992.
Baculovirus expression vectors a laboratory manual. W. H.
Freeman & Co., New York, N.Y.
|
| 31.
|
Orenstein, J. M.,
M. S. Meltzer,
T. Phipps, and H. E. Gendelman.
1988.
Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study.
J. Virol.
62:2578-2586[Abstract/Free Full Text].
|
| 32.
|
Paillart, J. C., and H. G. Gottlinger.
1999.
Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of gag membrane targeting.
J. Virol.
73:2604-2612[Abstract/Free Full Text].
|
| 33.
|
Parent, L. J.,
R. P. Bennett,
R. C. Craven,
T. D. Nelle,
N. K. Krishna,
J. B. Bowzard,
C. B. Wilson,
B. A. Puffer,
R. C. Montelaro, and J. W. Wills.
1995.
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
69:5455-5460[Abstract].
|
| 34.
|
Pautrat, G.,
M. Suzan,
D. Salaun,
P. Corbeau,
C. Allasia,
G. Morel, and P. Filippi.
1990.
Human immunodeficiency virus type-1 infection of U937 cells promotes cell differentiation and a new pathway of viral assembly.
Virology
179:749-758[CrossRef][Medline].
|
| 35.
|
Pearce-Pratt, R.,
D. Malamud, and D. M. Phillips.
1994.
Role of the cytoskeleton in cell-to-cell transmission of human immunodeficiency virus.
J. Virol.
68:2898-2905[Abstract/Free Full Text].
|
| 36.
|
Pepinsky, R., and V. Vogt.
1979.
Identification of retrovirus matrix proteins by lipid-protein cross-linking.
J. Mol. Biol.
131:819-837[CrossRef][Medline].
|
| 37.
|
Puffer, B. A.,
L. J. Parent,
J. W. Wills, and R. C. Montelaro.
1997.
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein.
J. Virol.
71:6541-6546[Abstract].
|
| 38.
|
Rey, O.,
J. Canon, and P. Krostad.
1996.
HIV-1 Gag protein associates with F-actin present in microfilaments.
Virology
220:530-534[CrossRef][Medline].
|
| 39.
|
Rhee, S.,
H. Hui, and E. Hunter.
1990.
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane.
J. Virol.
64:3844-3852[Abstract/Free Full Text].
|
| 40.
|
Rhee, S., and E. Hunter.
1991.
Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid.
EMBO J.
10:535-546[Medline].
|
| 41.
|
Rhee, S., and E. Hunter.
1987.
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids.
J. Virol.
61:1045-1053[Abstract/Free Full Text].
|
| 42.
|
Rhee, S., and E. Hunter.
1990.
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus.
Cell
63:77-86[CrossRef][Medline].
|
| 43.
|
Rhee, S., and E. Hunter.
1990.
Structural role of the matrix protein of type D retroviruses in Gag polyprotein stability and capsid assembly.
J. Virol.
64:4383-4389[Abstract/Free Full Text].
|
| 44.
|
Royer, M.,
M. Cerutti,
B. Gay,
S.-S. Hong,
G. Devauchelle, and P. Boulanger.
1991.
Functional domains of HIV-1 Gag-polyprotein expressed in baculovirus-infected cells.
Virology
184:417-422[CrossRef][Medline].
|
| 45.
|
Sakalian, M.,
S. Parker,
R. Weldon, Jr., and E. Hunter.
1996.
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro.
J. Virol.
70:3706-3715[Abstract].
|
| 46.
|
Sakalian, M.,
R. Weldon, Jr., and E. Hunter.
1999.
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus.
J. Virol.
73:8073-8082[Abstract/Free Full Text].
|
| 47.
|
Sambrook, J.,
E. F. Fritsch, and T. Manatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed., vol. 1.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 48.
|
Shioda, T., and H. Shibuta.
1990.
Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV.
Virology
175:139-148[CrossRef][Medline].
|
| 49.
|
Sommerfelt, M.,
C. Roberts, and E. Hunter.
1993.
Expression of simian type D retroviral (Mason-Pfizer monkey virus) capsids in insect cells using recombinant baculovirus.
Virology
192:298-306[CrossRef][Medline].
|
| 50.
|
Sonigo, P.,
C. Barker,
E. Hunter, and S. Wain-Hobson.
1986.
Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus.
Cell
45:375-385[CrossRef][Medline].
|
| 51.
|
Spearman, P., and L. Ratner.
1996.
Human immunodeficiency virus type 1 capsid formation in reticulocyte lysates.
J. Virol.
70:8187-8194[Abstract].
|
| 52.
|
Spearman, P.,
J. Wang,
N. Vander Heyden, and L. Ratner.
1994.
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly.
J. Virol.
68:3232-3242[Abstract/Free Full Text].
|
| 53.
|
Streblow, D. N.,
M. Kitabwalla, and C. D. Pauza.
1998.
Gag protein from human immunodeficiency virus type 1 assembles in the absence of cyclophilin A.
Virology
252:228-234[CrossRef][Medline].
|
| 54.
|
Takahashi, R. H.,
K. Nagashima,
T. Kurata, and H. Takahashi.
1999.
Analysis of human lymphotropic T-cell virus type II-like particle production by recombinant baculovirus-infected insect cells.
Virology
256:371-380[CrossRef][Medline].
|
| 55.
|
Temin, H. M.
1992.
Origin and general nature of retroviruses, p. 1-18.
In
J. A. Levy (ed.), The Retroviridae, vol. 1. Plenum Press, New York, N.Y.
|
| 56.
|
Vogt, V. M.
1996.
Proteolytic processing and particle maturation.
Curr. Top. Microbiol. Immunol.
214:94-131.
|
| 57.
|
Weldon, R., Jr.,
W. Parker,
M. Sakalian, and E. Hunter.
1998.
Type D retrovirus capsid assembly and release are active events requiring ATP.
J. Virol.
72:3098-3106[Abstract/Free Full Text].
|
| 58.
|
Wilk, T.,
B. Gowen, and S. D. Fuller.
1999.
Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein.
J. Virol.
73:1931-1940[Abstract/Free Full Text].
|
| 59.
|
Wills, J. W., and R. C. Craven.
1991.
Form, function and use of retroviral Gag proteins.
AIDS
5:639-654[Medline].
|
| 60.
|
Yamshchikov, G. V.,
G. D. Ritter,
M. Vey, and R. W. Compans.
1995.
Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system.
Virology
214:50-58[CrossRef][Medline].
|
| 61.
|
Yasuda, J., and E. Hunter.
1998.
A proline rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release.
J. Virol.
72:4095-4103[Abstract/Free Full Text].
|
| 62.
|
Yuan, X.,
X. Yu,
T. Lee, and M. Essex.
1993.
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix block intracellular transport of the Gag precursor.
J. Virol.
67:6387-6394[Abstract/Free Full Text].
|
Journal of Virology, January 2000, p. 784-795, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Andersen, K. B., Diep, H. A., Zedeler, A.
(2006). Murine leukemia virus transmembrane protein R-peptide is found in small virus core-like complexes in cells. J. Gen. Virol.
87: 1583-1588
[Abstract]
[Full Text]
-
Abdurahman, S., Hoglund, S., Goobar-Larsson, L., Vahlne, A.
(2004). Selected amino acid substitutions in the C-terminal region of human immunodeficiency virus type 1 capsid protein affect virus assembly and release. J. Gen. Virol.
85: 2903-2913
[Abstract]
[Full Text]
-
Serhan, F., Jourdan, N., Saleun, S., Moullier, P., Duisit, G.
(2002). Characterization of Producer Cell-Dependent Restriction of Murine Leukemia Virus Replication. J. Virol.
76: 6609-6617
[Abstract]
[Full Text]
-
Parker, S. D., Hunter, E.
(2001). Activation of the Mason-Pfizer monkey virus protease within immature capsids invitro. Proc. Natl. Acad. Sci. USA
10.1073/pnas.251460998v1
[Abstract]
[Full Text]
-
Parker, S. D., Wall, J. S., Hunter, E.
(2001). Analysis of Mason-Pfizer Monkey Virus Gag Particles by Scanning Transmission Electron Microscopy. J. Virol.
75: 9543-9548
[Abstract]
[Full Text]
-
Eastman, S. W., Linial, M. L.
(2001). Identification of a Conserved Residue of Foamy Virus Gag Required for Intracellular Capsid Assembly. J. Virol.
75: 6857-6864
[Abstract]
[Full Text]
-
Tritel, M., Resh, M. D.
(2001). The Late Stage of Human Immunodeficiency Virus Type 1 Assembly Is an Energy-Dependent Process. J. Virol.
75: 5473-5481
[Abstract]
[Full Text]
-
Bieniasz, P. D., Cullen, B. R.
(2000). Multiple Blocks to Human Immunodeficiency Virus Type 1 Replication in Rodent Cells. J. Virol.
74: 9868-9877
[Abstract]
[Full Text]
-
Rumlova-Klikova, M., Hunter, E., Nermut, M. V., Pichova, I., Ruml, T.
(2000). Analysis of Mason-Pfizer Monkey Virus Gag Domains Required for Capsid Assembly in Bacteria: Role of the N-Terminal Proline Residue of CA in Directing Particle Shape. J. Virol.
74: 8452-8459
[Abstract]
[Full Text]
-
Parker, S. D., Hunter, E.
(2001). Activation of the Mason-Pfizer monkey virus protease within immature capsids invitro. Proc. Natl. Acad. Sci. USA
98: 14631-14636
[Abstract]
[Full Text]